1
|
Kim YJ, Ahn HJ, Lee SH, Lee MH, Kang KS. Effects of conditioned media from human umbilical cord blood-derived mesenchymal stem cells in the skin immune response. Biomed Pharmacother 2020; 131:110789. [PMID: 33152947 DOI: 10.1016/j.biopha.2020.110789] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 09/12/2020] [Accepted: 09/17/2020] [Indexed: 12/12/2022] Open
Abstract
Atopic dermatitis (AD) is an inflammatory skin disease in which type 2 allergic inflammation plays a critical role. In this study, the anti-inflammatory effect of conditioned media from human umbilical cord blood-derived mesenchymal stem cells (USC-CM) was investigated in order to apply it as an effective treatment with a low risk of side effects that can overcome the limitations of AD treatment which is currently in use. We found that USC-CM has various growth factors and cytokines associated with anti-inflammatory effect. RT-PCR and ELISA analysis showed that USC-CM inhibited the levels of type 2 cytokine and chemokine Thymus and activation-regulated chemokine (TARC), TNF-α and IL-6 in TNF-α/IFN-γ-stimulated HaCaT cells. In addition, USC-CM inhibited IL-4 and IL-13 levels in Th2 cells. Therefore, the results of our study demonstrated that USC-CM has anti-inflammatory effect in TNF-α/IFN-γ-stimulated HaCaT cells which associated with the inhibition of the immunoglobulin (IgE) secretion by activating B cell line. Our In vivo results showed that when the USC-CM was applied to lesions of patients with the mild AD for 4 weeks, the skin barrier was strengthened by increasing the level of Corneometer and decreasing the value of transepidermal water loss (TEWL). In conclusion, the results suggest that USC-CM may have therapeutic effect for AD as cosmetics and drug materials.
Collapse
Affiliation(s)
- Yoon-Jin Kim
- Derma Science R&D Center, Primoris International CO., LTD., #1504, A Bldg., 60 Haahn-ro, Gwangmyeong-si, Gyeonggi-do, 14332, Republic of Korea
| | - Hee-Jin Ahn
- Cytotherapy R&D Center, PRIMORIS CO., LTD., #1504, A Bldg., 60 Haahn-ro, Gwangmyeong-si, Gyeonggi-do, 14332, Republic of Korea
| | - Seung-Hee Lee
- Stem Cells and Regenerative Bioengineering Institute, Kangstem Biotech Co., Ltd., 2nd Floor, Biotechnology Center, #81 Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea
| | - Mi-Hye Lee
- GMP Center, Kangstem Biotech Co., Ltd., 6nd Floor, A Bldg., 60 Haahn-ro, Gwangmyeong-si, Gyeonggi-do, 14332, Republic of Korea
| | - Kyung-Sun Kang
- Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea; Cytotherapy R&D Center, PRIMORIS CO., LTD., #1504, A Bldg., 60 Haahn-ro, Gwangmyeong-si, Gyeonggi-do, 14332, Republic of Korea.
| |
Collapse
|